GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration
Under the terms of the agreement, Arvinas will leverage GNS’ Gemini Virtual Patient models to better understand the underlying disease biology, its course and how potential drugs might work at the individual patient level. This will help Arvinas researchers discover and prioritize novel drug targets and drug candidates, simulate clinical trials to better understand disease drivers for various clinical outcomes, better select patients for clinical trials, and determine which treatments are most effective for particular types of patients.
Angela CacacePh.D., Senior Vice President of Neuroscience and Platform Biology at Arvinas, said, “We believe this collaboration will provide new insights and help us understand the mechanisms underlying complex neurodegenerative diseases. to inform our discovery and development efforts to improve patient outcomes.”
“We are committed to supporting the essential work Arvinas is doing to discover and develop breakthrough therapies that help patients who suffer from these diseases,” said Joseph F. Donahue, Commercial Director at GNS Healthcare. “These diseases affect so many families and we are proud to be able to contribute to potential treatments that lead to better outcomes for them.”
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade pathogenic proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to design proteolysis-targeting chimeras, or PROTAC® Targeted Protein Degraders, which are designed to harness the body’s own natural protein elimination system to degrade and eliminate selectively and efficiently the pathogenic proteins. In addition to its strong preclinical pipeline of PROTAC® protein degraders against validated and “indrugable” targets, the company has three clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with cancer castration-resistant metastatic prostate; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
For more information, visit www.arvinas.com
About GNS Health
GNS Healthcare is the leader in applying causal AI and simulation technology to help pharmaceutical and biotechnology companies discover and develop new medicines faster. GNS’ patented AI unlocks new insights from multi-omics and real-world data leading to the discovery and prioritization of new biological targets, more efficient clinical trials, and patients likely to respond to therapies. Gemini Virtual Patient models in oncology, autoimmune diseases, and neurology allow researchers and data scientists to simulate clinical trials, disease progression, and drug response at the individual patient level in diverse patient cohorts. GNS partners include seven of the top ten pharmaceutical companies, leading research centers, medical societies and patient advocacy groups globally, and our advisory board is comprised of a renowned group of scientific experts and medical.
For more information, please visit www.gnshealthcare.com
SOURCE GNS Health